These results showed that A22 could bind to and stabilize BCL-2 promoter i-motif resulting in up-regulation of BCL-2 expression, which could become a promising approach for anti-apoptosis based on our study in NAFLD/NASH mice model in vivo. This evidence concerns the gene BCL2 and metabolic dysfunction-associated steatotic liver disease.